Home Uncategorized

Uncategorized

Random

atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update

atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments

MindMed Announces $50 Million Bought Deal Public Offering

atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial...

atai Life Sciences to Participate in Upcoming January Investor Conference

atai Life Sciences to Participate in Upcoming June Healthcare Conferences

Psychedelics Versus Cannabis: Exploring their Impact on Treating Mental Illness

atai Life Sciences Reports First Quarter 2023 Financial Results and Announces...

Psychedelic legend “the Acid King” William Leonard Pickard Announced as Keynote...

atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as...

atai Life Sciences Reports First Quarter 2022 Financial Results and Business...

atai Life Sciences Announces First Subject Dosed in Phase 1 Trial...

atai Life Sciences Announces Dosing of First Patient in Part 2...

12 3...13 Page 1 of 13

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy...

The Psychedelic News Feed: December 1 – 7, 2025

The Psychedelic News Feed: November 24 – 30, 2025

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.